Published in Br J Cancer on June 08, 2010
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One (2015) 1.03
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
Identification of differentially expressed serum proteins in gastric adenocarcinoma. J Proteomics (2015) 0.83
Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer (2012) 0.81
Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies. Oncologist (2014) 0.77
Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Rep (2013) 0.75
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res (2015) 0.75
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem (2003) 8.13
Renal cell carcinoma. Lancet (2009) 6.92
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest (1996) 1.97
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol (2008) 1.60
Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol (2009) 1.58
Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol (2009) 1.57
Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci (2009) 1.57
Serum and plasma proteomics. Chem Rev (2007) 1.56
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res (2005) 1.45
C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer (2007) 1.43
Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest (2004) 1.39
Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int (2005) 1.27
Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res (2003) 1.26
Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol (2006) 1.19
Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res (2005) 1.18
Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int (2006) 1.16
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol (2009) 1.15
Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer (2006) 1.12
Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer (2001) 1.06
A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int (2003) 1.05
Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am (2008) 1.05
Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics (2008) 1.04
Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol (2001) 1.03
Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett (2003) 1.02
Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl (1999) 1.02
Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Electrophoresis (1996) 1.01
Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis (2005) 1.00
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett (2008) 1.00
Applications of SELDI-MS technology in oncology. J Cell Mol Med (2008) 0.98
Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med (2007) 0.97
The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol (1995) 0.95
Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? Nat Clin Pract Oncol (2006) 0.87
Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol (2004) 0.86
Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest (2007) 0.85
Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int (2008) 0.84
Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin Chem Lab Med (2009) 0.84
Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles--initial evaluation using low molecular weight serum peaks. Proteomics (2009) 0.83
Identification of the SELDI ProteinChip human serum retentate by microcapillary liquid chromatography-tandem mass spectrometry. J Proteome Res (2006) 0.80
Cathepsin D activity protects against development of type AA amyloid fibrils. Eur J Clin Invest (2009) 0.79
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet (2001) 5.18
Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med (1989) 4.72
Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer. Gut (1983) 4.47
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet (1980) 4.21
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer (1998) 3.93
The successful implementation of pharmaceutical practice guidelines. Analysis of associated outcomes and cost savings. SWiPE Group. Systematic Withdrawal of Perioperative Expenses. Anesthesiology (1997) 3.92
Trends in perinatal transmission of HIV/AIDS in the United States. JAMA (1999) 3.86
Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito. Nature (1998) 3.56
Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev (2001) 3.46
HeartCare: an Internet-based information and support system for patient home recovery after coronary artery bypass graft (CABG) surgery. J Adv Nurs (2001) 3.36
Classification and surgical treatment of incisional hernia. Results of an experts' meeting. Langenbecks Arch Surg (2001) 3.01
BMI from 3-6 y of age is predicted by TV viewing and physical activity, not diet. Int J Obes (Lond) (2005) 2.99
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Myths in management of colorectal malignancy. Br J Surg (1997) 2.68
The impact of long-term acute-care facilities on the outcome and cost of care for patients undergoing prolonged mechanical ventilation. Crit Care Med (2000) 2.66
Endoscopic guided percutaneous tracheostomy: early results of a consecutive trial. J Trauma (1990) 2.64
Marriage, monogamy and HIV: a profile of HIV-infected women in south India. Int J STD AIDS (2000) 2.59
Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. J Clin Oncol (1999) 2.59
Bacterial infection in cystic fibrosis. Arch Dis Child (1972) 2.58
Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J (1990) 2.53
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med (2000) 2.46
A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology (2000) 2.44
Communication between GPs and cooperatives is poor for terminally ill patients. BMJ (1997) 2.41
The development of a method for assessing the quality of life of cancer patients. Br J Cancer (1984) 2.23
Factors delaying surgical treatment of hip fractures in elderly patients. Ann R Coll Surg Engl (2003) 2.22
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet (2001) 2.19
Interferon therapy for condylomata acuminata. N Engl J Med (1986) 2.16
Analysis of Tn7 transposition. Mol Gen Genet (1986) 2.08
On the mechanism of the post-activation depression of the H-reflex in human subjects. Exp Brain Res (1996) 2.05
Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis (1990) 2.04
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res (1987) 2.03
Report on hypertension. Can Med Assoc J (1978) 2.01
Parenteral acyclovir therapy for herpesvirus infections in man. Lancet (1979) 1.99
Laryngospasm during subarachnoid block. Br J Anaesth (2005) 1.99
Laparoscopic cholecystectomy for acute cholecystitis: is it really safe? World J Surg (1996) 1.98
Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology. Br J Cancer (2002) 1.98
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Cancer in old age--is it inadequately investigated and treated? BMJ (1999) 1.95
Next-generation sequencing: the solution for high-resolution, unambiguous human leukocyte antigen typing. Hum Immunol (2010) 1.95
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res (2000) 1.88
Transforming the tobacco market: why the supply of cigarettes should be transferred from for-profit corporations to non-profit enterprises with a public health mandate. Tob Control (2005) 1.88
A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer (2006) 1.86
Selective neuronal targeting in prion disease. Neuron (1997) 1.82
The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl (1992) 1.81
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol (1993) 1.79
Screening for Duchenne muscular dystrophy. Arch Dis Child (1989) 1.78
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med (2000) 1.76
Anogenital warts in childhood. Child Abuse Negl (1989) 1.75
Reduction in circulating levels of CD4-positive lymphocytes in acute pancreatitis: relationship to endotoxin, interleukin 6 and disease severity. Br J Surg (1993) 1.73
Rationale, design and methods for process evaluation in the HEALTHY study. Int J Obes (Lond) (2009) 1.70
Deliberating about bioethics. Hastings Cent Rep (1997) 1.69
Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene (2010) 1.69
Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A (1993) 1.67
Study of restriction fragment length polymorphism analysis and spoligotyping for epidemiological investigation of Mycobacterium bovis infection. J Clin Microbiol (1999) 1.64
Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting. JAMA (1996) 1.64
Rationale, design and methods of the HEALTHY study behavior intervention component. Int J Obes (Lond) (2009) 1.61
Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med (2001) 1.59
A survey of Campylobacter and other bacterial contaminants of pre-market chicken and retail poultry and meats, King County, Washington. Am J Public Health (1986) 1.59
Acquisition of protease resistance by prion proteins in scrapie-infected cells does not require asparagine-linked glycosylation. Proc Natl Acad Sci U S A (1990) 1.59
The prognostic value of renal resistance during hypothermic machine perfusion of deceased donor kidneys. Am J Transplant (2011) 1.59
Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis. J Rheumatol (1997) 1.58
Septic arthritis following intra-articular steroid injection of the knee--a survey of current practice regarding antiseptic technique used during intra-articular steroid injection of the knee. Clin Rheumatol (2003) 1.56
Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br J Dermatol (2001) 1.56
Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J Pediatr (1991) 1.55
The molecular detection of circulating tumour cells. Br J Cancer (1995) 1.55
Quality of sleep, fatigue and daytime sleepiness in migraine - a controlled study. Cephalalgia (2009) 1.53
A descriptive analysis of children's playground injuries in the United States 1990-4. Inj Prev (1997) 1.52
Constructing deletions with defined endpoints in Drosophila. Proc Natl Acad Sci U S A (1990) 1.51
Surgical revascularisation for childhood moyamoya. Childs Nerv Syst (2012) 1.51
Comparison of genome screens for two independent cohorts provides replication of suggestive linkage of bone mineral density to 3p21 and 1p36. Am J Hum Genet (2002) 1.51
Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet (2002) 1.50
Primary immunisations in Liverpool. II: Is there a gap between consent and completion? Arch Dis Child (1993) 1.49
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis (2000) 1.48
Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer (1993) 1.48
Structural analysis of membrane-bound retrovirus capsid proteins. EMBO J (1997) 1.48
[Arterial air embolism as a complication of blunt thoracic trauma]. Anaesthesist (1999) 1.48
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer (2006) 1.48
Proteomics: new perspectives, new biomedical opportunities. Lancet (2000) 1.46
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br J Cancer (1978) 1.46
Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant (2015) 1.46
Brucellosis associated with thrombocytopenia. Saudi Med J (2000) 1.45
Quantitative measurement of calcium flux through muscle and neuronal nicotinic acetylcholine receptors. J Neurosci (1994) 1.45
Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol (1998) 1.43
Uncertainty and opposition of medical students toward assisted death practices. J Pain Symptom Manage (2001) 1.43
Aggressive management of non-small cell lung cancer with synchronous solitary brain metastasis. Clin Oncol (R Coll Radiol) (2004) 1.42
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 1.40
Baroreceptor, not left ventricular, dysfunction is the cause of hemodialysis hypotension. Clin Nephrol (1989) 1.40
Double stapled transabdominal anastomosis for one-stage resection of acute sigmoid volvulus. Br J Surg (1997) 1.40
Novel urothelium specific gene expression identified by differential display reverse transcriptase-polymerase chain reaction. J Urol (2006) 1.40
Fixed drug eruptions in children. J Pediatr (1999) 1.40